Pr ot oc ol 2 0 2 1 -0 9 9 4  
Versi o n Date: 0 2/ 0 6/ [ADDRESS_77342] u d y  Titl e : I nt r a o p e r ati v e a r o m at h e r a p y v e r s u s pl a c e b o 
f o r  P o rt -a-C at h  pl a c e m e nt  u n d e r M o nit o r e d A n e st h e si a C a r e . 
A r a n d o mi z e d c o nt r oll e d t ri al  
P ri n ci p al  I n v e sti g at o r  ( PI) : N eil B ail a r d  MD 
C o -I n v e sti g at o r (s) ( C o -I) : J u a n P. C at a  M D  
C oll a b o r at o r (s):  C a ri n H a g b e r g M D , J eff r e y C e r n y M D, S p e n c e r K e e M D, K at y 
F r e n c h M D , Ali ci a  K o w al s ki M D , Eli z a b et h R e b ell o M D  
St ati sti c ia n : L ei F e n g  
S p o n s o r  N a m e : B E E K L E Y C O R P O R A TI O N  Pr o pri et ar y of M D A n d er s o n C a n c er C e nt er 
3URWRFRO
9HUVLRQ'DWH
3DJHRI
SUMMARY TABLE
TitleIntraoperative aromatherapy versus placebo for Port-
a-Cath placement under Monitored Anesthesia Care
(MAC). A randomized controlled trial.
Study Population Size
(# of patients)70
Study Design This is a prospective, controlled, randomized trial.
Primary ObjectiveTo compare the time to readin ess for discharge (minutes) from 
Post-Anesthesia Care Unit (PACU) after Port-a- Cath placement 
surgery between patients who are randomized to receive 
intraoperative aromatherapy versus placebo
Secondary ObjectivesTo evaluate the following secondary outcomes:
1) Anxiety score (HADS) in preoperative holding area
2) Midazolam use intraoperatively (mg)
3) Intraoperative opi[INVESTIGATOR_2441] (morphine equivalents)
4) Intraoperative anti-emetic use
5) Time to first occurrence of  postoperative nausea or 
vomiting (PONV) in PACU
6) Rate and intensit y of PONV in PACU
7) Antiemetic use in PACU
8) Opi[INVESTIGATOR_70995] (morphine equivalents)
9) Pain intensity in PACU (0- 10 numerical rating scale)
10)Patient satisfaction in PACU
Inclusion Criteriax Adult patients ( â‰¥18 years old) 
x Undergoing Port-a-Cath placement surgery under 
Monitored Anesthesia CareProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJHRI
x Signed Informed Consent form
Exclusion Criteriax Patients undergoing other surgical procedures 
during Port-a-Cath placement (including explantation of 
a Port-a-Cath or ot her previous vascular access device)
x Patients requiring general anesthesia or those not eligible 
for MAC
x Patients allergic or sensitive to plants, essential oils, or 
any of the medications used in this study
x Patients with history of G6PD deficiency
x Patients with history of atrial fibrillation
x Patients unable to complete study questionnaires
x Patients who are completely anosmic or who have history 
of intolerance to aromatherapy.
x Patients who have been taking any opi[INVESTIGATOR_70996] [ADDRESS_77343] been taki ng any benzodiazepi[INVESTIGATOR_70997] 30 days or more
Study Procedures
Pretreatment
EvaluationEligible subjects will be identified from within the patient 
population of the study site. There will be no advertisements 
for study subjects.
On-Study VisitsAll study procedures and data co llection will occur on the day 
of surgery.
Follow-up Visits None
End of Study Visit NoneProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJHRI
Brief Analysis PlanWe will summarize continuous demographics and clinical 
variables using means, standa rd deviations, medians and 
ranges. Categorical demographic variables and clinical 
variables will be summarize d through frequencies and 
percentages. Fisherâ€™s exact test or Chi- square test will be 
used to evaluate the association between two categorical 
variables of interest. Wilc oxon-rank sum test or t- test will be 
used to compare continuous outcomes between treatment 
groups. Linear/logist ic regression model may be fitted to 
assess the effect of important covariates on the 
primary/secondary endpoints.
1. OBJECTIVES
The primary objective is to compare th e time to readiness for discharge from PACU 
(minutes) after Port-a-Cath placement surger y between patients who are randomized to 
receive intraoperative aromatherapy versus placebo
Secondary Objectives are to evaluate  the following secondary outcomes: 
1. Anxiety score (HADS) in preoperative holding area
2. Midazolam use intraoperatively (mg)
3. Intraoperative opi[INVESTIGATOR_2441] (morphine equivalents)
4. Intraoperative anti-emetic use
5. Time to first occurrence of postop erative nausea or vomiting in PACU
6. Rate and intensit y of PONV in PACU
7. Antiemetic use in PACU
8. Opi[INVESTIGATOR_70995] (morphine equivalents)
9. Pain intensity in PACU (0- 10 numerical rating scale)
10. Patient satisfaction in PACUProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJHRI
2. BACKGROUND
2.1. Porta-Catheter placement
A Porta-Catheter (Port-a-Cath) is a vascular a ccess device placed completely under the skin 
on either side of the chest. The device is rout inely placed to deliver chemotherapy treatments, 
obtain blood draws or infuse fluids intraven ously. Port-a-Cath placement may be performed 
under general anesthesia or sedation (Monitored Anesthesia Care, MAC) depending on patient 
health factors and preference. Intraoperativ e anxiety is a common problem when MAC instead 
of general anesthesia is used during minor surg ical procedures such as Port-a-Cath placement. 
Johansson et al. reported that 60% of the patients felt â€œunpleasantâ€ during Port-a-Cath 
insertion under local anesthesia. I ntraoperative anxiety is associated with a negative influence 
on pain perception, increased use of sedati ves like benzodiazepi[INVESTIGATOR_1651] (i.e., midazolam) and 
opi[INVESTIGATOR_2438], prolonged recovery a fter surgery and unnecessary post procedural hospi[INVESTIGATOR_059]. 
Benzodiazepi[INVESTIGATOR_70998] e calming effects via binding to GABA Areceptors.
Fatigue, confusion, respi[INVESTIGATOR_2341], and re stlessness are undesira ble adverse effects of 
midazolam and opi[INVESTIGATOR_70999] â€™ability to actively participate in their intra- and 
postoperative care. Furthermore, Chang et al. fo und that the use of benzodiazepi[INVESTIGATOR_71000]â€™s satisfaction during Port -a-Cath placement. Non-benz odiazepi[INVESTIGATOR_71001]. Intraoperative 
sedation with i.v. dexmedetomidine has de monstrated significant reduction in the 
postoperative opi[INVESTIGATOR_71002], as reported by [CONTACT_71035]. However, dexmedetomidine can cause 
hypotension and bradycardia and prolonged sedation. As a result of the potential adverse of 
benzodiazepi[INVESTIGATOR_71003], and opi[INVESTIGATOR_2438], non- pharmacological therapi[INVESTIGATOR_71004].
Music, a non-pharmacological intervention, ha s been studied to redu ce anxiety in minor 
surgery. While Schaal et al. indicated that perioperative music did not reduce anxiety or 
cortisol levels during Port-a-Cath placement,  McDaniel et al. reported that music via 
headphones (though not via loud speakers) resulted in signific antly lower anxiety after the 
procedure compared to the beginning. However, a major deficiency in McDanielâ€™s study was 
the lack of randomization to the studied interventions and that musical therapy can interfere Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJHRI
with the patientsâ€™ ability to follow commands . Therefore, it is important to examine other non-
pharmacological intraoperative interventions which may be able to reduce anxiety and the use 
of excessive doses of midazolam and opi[INVESTIGATOR_2438], as well as improve recovery after Port-a-Cath 
placement.
2.[ADDRESS_77344] and an inhibitor of  serotoninergic targets. Yuan et al. proposed 
that both molecules also exert anti-inflammatory effects by [CONTACT_71036]-kB and 
the release of pro-inflammatory cytokines (i.e., TNF-a, IL-1B and PGE2). The sedative effects 
of lavender aromatherapy have been studied in multiple clinical studies. A meta-analysis by 
[CONTACT_71037]. showed a lack of conc lusive evidence to indicate aromatherapy for the treatment of 
preoperative anxiety. However, more recent  studies have shown promising results. For 
instance, Wotman et al. demonstrated a reduct ion in preoperative anxiety in ambulatory 
surgery patients treated with aromatherapy unde rgoing procedures in general otolaryngology. 
A major limitation of the stud y was the lack of a placebo-co ntrolled arm. Comparable results
were reported by [CONTACT_71038]. in a pi[INVESTIGATOR_71005] ÄŸluet al. in a randomized controlled trial. Ki m et al. in a study of acupuncture needle Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJHRI
insertion found that subjects who inhaled a lave nder oil for 5 minutes demonstrated a decrease 
in anxiety, less needle insertion pain, and Bi spectral Index (processed EEG) changes suggestive 
of sedation.
Peppermint oil has long been valued for its anti nausea effect. Grigoleit et al. found that 
menthol and menthone, the main constituents o f peppermint oil, appear to act as smooth 
muscle relaxants through calcium channel bl ockade when the oil is orally ingested. As an
inhaled vapor, peppermint oil likely acts through another mechanism, such as by [CONTACT_71039]. Hines et al., in a 
systematic review, found that aromatherapy appeared to be no better than placebo in 
preventing nausea, although there was some evidence that patients who had received 
aromatherapy required fewer an tiemetic medications. Hines et  al. rated the quality of the 
included studies as moderate to very low by [CONTACT_71040] (Grading of Recommendations, 
Assessment, Development and Evaluations) criter ia, however. More recently, Ahmadi et al.
found peppermint oil aromatherapy to be effective in reducing nausea after abdominal surgery. 
Maghami et al. found that peppermint oil aromathe rapy was effective in reducing nausea after 
open-heart surgery, although the peppermint oil was delivered via in-line nebulizer in patients 
who remained intubated, limiting  the studyâ€™s generalizability. 
Because the existing literature is equivocal for both lavender and peppermint 
aromatherapy, we believe that a well-designed placebo-controlled trial may help to resolve 
some of the uncertainty as to their clinical effectiveness in the ambulatory perioperative 
setting. As well, to our knowledge there have b een no studies of arom atherapy conducted on 
subjects undergoing surgery performed under Monitored Anesthesia Care (versus general 
anesthesia).
Our primary hypothesis is that preoperative and intraoperative placement of an active 
lavender-peppermint patch (vs. placebo patch) will re sult in a shorter time to discharge-
readiness in the post-anesthesia care unit ( PACU). Secondary hypotheses are that subjects 
randomized to active aromatherapy patch will  have lower midazolam use intraoperatively 
(mg), lower intraoperative opi[INVESTIGATOR_2441] (m orphine equivalents), lower supplemental 
intraoperative antiemetic use, longer time to first occurrence of PONV, lower rate and intensity 
of post-operative nausea or vomiting in PACU, lower rate of rescue an tiemetic use in PACU, 
lower maximum pain intensity in PACU (0-10 numerical rating scale), and higher patient 
satisfaction in PACU (Likert scale).
3URWRFRO
9HUVLRQ'DWH
3DJHRI
3. Background Device Information
AromatabsÂ® are inhalational aromatherapy patches intended to self- adhere to a patientâ€™s 
gown or clothing and release pleasant odor s over several hours (up to 8 hours, per 
manufacturer). The essential oils themselves do not conta ct with the patientâ€™s skin, since the 
patch is contained in a pl astic envelope, and it is this plasti c envelope that is affixed to the 
patientâ€™s gown or clothing. https://beekley.com/product-detai ls/elequil-aromatabs-lavender-
peppermint-373
The AromatabsÂ® patches will be  stored in a secured cabinet in the study team office, 
following storage guidelines from the manufacturer. Each patch will be labeled in accordance
with FDA regulations and institutional policies be fore use. Detailed records of receipt, use or 
disposition will be maintained by [CONTACT_079] [INVESTIGATOR_71006].
This is study is not intended to  promote nor market AromatabsÂ®.
4. Study Design
This is a prospective randomized controlled trial.
5. Discussion of Study Population
5.1 Study Characteristics
Number of Subjects: This study will enroll [ADDRESS_77345] 62 eligible and treated patients.
5.2 Inclusion and Exclusion Criteria
a) Inclusion Criteria
Æ”Adult patients ( â‰¥18 years old) Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJHRI
Æ”Port-a-Cath placement under Monitored Anesthesia Care
Æ”Signed informed consent
b) Exclusion Criteria
xPatients undergoing other surgical pr ocedures during Port-a-Cath placement
(including explantation of a Port-a-Cath or  other previous vascular access device)
xPatients requiring general anesthes ia or those not eligible for MAC
xPatients allergic or sensitive to plants, esse ntial oils, or any of the medications used in 
this study
xPatients with history of G6PD deficiency
xPatients with history of atrial fibrillation 
xPatients unable to complete study questionnaires
xPatients who are completely anosmic or  who have history of intolerance to 
aromatherapy
xPatients who have been taking an y opi[INVESTIGATOR_70996] [ADDRESS_77346] Identification and RecruitmentEligible subjects will be identified from within the patient population of the study site by 
[CONTACT_8362]. Advertiseme nts for study subjects are not anticipated.
6.2 Consent Process
Subjects deemed eligible to participate in the study will be explained in detail the purpose, 
nature, and procedures of the study, as well as the potential risks, benefits, and alternatives. 
They will be given a consent form to read and if they so choose, to discuss with friends, family, 
and other clinicians. They will be invited to ask questions and, after all questions are answered
to their satisfaction, invited to sign the consen t form. The Principal Investigator [INVESTIGATOR_71007] e in the consenting process to ensure the subjectProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
has full understanding of the procedure and r isks. No study-specific procedure will be
performed before the consent form is signed.
A separate consent document for the port-a-cath will be explained by [CONTACT_71041].
All consents will be signed electronically within the medical record on a MD Anderson 
Cancer Center password protected computer.
6.[ADDRESS_77347].
7. Methods and Study Procedures
7.1 Pretreatment EvaluationThe PI/Co-PI/research coordinator of the study will evaluate the inclusion/exclusion
criteria. Patients will be approached while in the preoperative area to discuss participation in
the study. The PI/Co-PI/research coordinator will ensure that patients are properly informed
about the study. All study related data will o nly be collected after the PI [INVESTIGATOR_12749]-PI [INVESTIGATOR_71008] e patient has signed the consent.
7.2 Procedure
Prior to surgery, subjects will be randomiz ed to either a lavender/peppermint patch 
(Elequis AromatabsÂ®, Beekley Corporation (https://beekley.com/aromatherapy/elequil-Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
aromatabs-aromatherapy-designed-for-the-clinical-setting) or a matching placebo patch. The 
assigned AromatabÂ® will be activated in the pr eoperative holding area by [CONTACT_71042] a folded towel placed as ide the subjectâ€™s head, contralateral 
to the side of the planned surgery. The to wel and AromatabÂ® will be transferred to the 
operating table with the subject as they arrive in the operative suite and maintained beside the 
subjectâ€™s head throughout the surgery.
All subjects will have standard physiologic moni tors placed on arrival to the operating room 
as per American Society of Anesthesiologists stan dards. They will have a nasal oxygen cannula 
or face mask placed to maintain adequate oxyg enation. An anesthesia provider (Certified 
Registered Nurse Anesthetist and/or Physician Anesthesiologist) will be present with them 
continuously from the time they leave the preope rative holding area until the time that they 
reach the PACU, and a handoff is given to the rece iving PACU nurse. Patients will be eligible to 
receive a maximum dose of [ADDRESS_77348] before 
transporting to the operative suite (standard of care, depending on patientâ€™s age , physiologic 
condition, and preference). The anesthesia provid er will administer intraoperative doses of 
midazolam i.v. and opi[INVESTIGATOR_2480] i.v. as needed, titrat ing to the desired level of sedation. The towel 
and AromatabÂ® will be discarded when the subj ect leaves the operating room. Prophylactic 
antiemetics will be administered  per anesthesiologist clinic al judgment, as Port-a-Cath 
placement is not known to carry a high risk of  postoperative nausea and vomiting (PONV), and 
general anesthesia is not being administered. Further, midazolam itself is known to have an 
antiemetic effect, as reported by [CONTACT_71043]. If  subjects report experience nausea or vomiting 
during the procedure, rescue em etics will be administered as necessary and per standard of 
care.
Postoperatively, all subjects  will be taken to the PACU an d cared for by a PACU nurse in 
standard fashion until they are discharged. Un der the current standard of care, the surgeon 
injects local anesthetic around the surgical wo und, thus very few current outpatient Port-a-
Cath patients require postoperat ive opi[INVESTIGATOR_2438]. If subjects have breakthrough pain, postoperative 
opi[INVESTIGATOR_71009]. If the 
subjects experience postoperative nausea or  vomiting in PACU, re scue emetics will be 
administered as necessary and per standard of  care. In the PACU, a research coordinator, 
research fellow, collaborator, or other member  of the research team will assess patient â€™s 
nausea/vomiting, pain intensity and satisfaction.Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
7.[ADDRESS_77349] a training session with all anesthesia collabor ators. The anesthesia 
collaborators will view a video demonstrating preparation and po sitioning of the aromatherapy 
patch/placebo patch on a folded towel, and placement of that towel next to the patientâ€™s head.
7.4 Data Collected from EMR
xDemographics (e.g., BMI, ag e, gender, and ethnicity)
xComorbidities (Charlson score)
xDosing and type of preoperative, intrao perative, and postoperative medications
xInformation regarding sedation  management intraoperatively
xSedation times (sedation start from placem ent of aromatab or placebo to procedure
end)
xProcedure times (procedure start to procedure end)
7.5 Additional Data Collected by [CONTACT_71044][INVESTIGATOR_71010] (H ADS) recorded in preoperative holding 
area after subject has given consent
xAldrete Parsap recovery scores, recorded  every 15 minutes in PACU from patient 
arrival (Anesthesia End timepoint) until a Parsap score of 18 or higher
xTime in minutes from Anesthesia End to  Aldrete Parsap score of 18 or higher
xPain intensity using the Verbal Numeric Ra ting Scale (0: no pain and [ADDRESS_77350] pain 
ever) every 15 minutes from procedure end until a Parsap score of 18 or more is 
reached
xNausea intensity using the Verbal Numeric Rating Scale (0: no nausea and [ADDRESS_77351]
nausea ever) every 15 minutes from procedur e end until a Parsap score of 18 or more 
is reached. Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
xVomiting: The number of epi[INVESTIGATOR_71011] 15 minutes 
from procedure end until a Parsap sc ore of 18 or more is reached. 
xPatient satisfaction (P atient-Reported Outcome, Likert scale), assessed  as soon as a 
Parsap score of [ADDRESS_77352] Withdrawals
Subjects may be withdrawn from the study for the following reasons:
1) Subject non-complianc e with study procedures
2) Unacceptable adverse events (safety or tolerability)
3) The subject may withdraw from the study at any time and for any reason
4) Clinician decision that it is in the best interest of the subject to withdraw from the
study
9. Safety and Reportable Events
9.[ADDRESS_77353]' s condition or laboratory results, which has or 
could have a deleterious effect on  the subject's health or well-being. An Adverse Event that is 
related to the investigational device may be re ferred to as an Adverse Device Effect (ADE). 
Unanticipated Adverse Device Effect (UADE): Any device related adverse event, the nature 
or severity of which is not consistent with or listed in the applicable product information (e.g., 
instructions for use, subject informed consen t document, subject information brochure [if 
applicable], promotional literature) or any ot her unanticipated seriou s problem associated Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
with a device that relates to the rights, safety , or welfare of subjects . These are dichotomous 
outcomes.
Expected Adverse Events
The experimental treatment is generally recogniz ed as safe. No adverse events are expected.
9.2 Serious Adverse Event
A serious adverse event is define d as any adverse medical experi ence that results in any of 
the following outcomes:
xDeath
xIs life-threatening
xRequires inpatient hospi[INVESTIGATOR_71012]/incapacity
xIs a congenital anomaly/birth defect
xRequires medical or surgical intervention to prevent permanent impairment or damage
9.3 Recording Adverse Events
All adverse events (AE) and serious adverse events (SAE) will be monitored from the 
time of procedure through end of the study. Th PI [INVESTIGATOR_71013].
An AE is defined as any undesirable clinical occurrence in a patient whether or not it is 
considered to be device related. In addition, the  definition of AE applies to any event with an 
onset post study procedure or to any underlying diseases, present at base line, that exacerbate 
in severity post study procedure. Therefore, an underlying disease that was present at the time 
of enrollment is not reported as an AE, but an y increase in the severity of the underlying 
disease is to be reported as an AE. All repo rted AEs must be recorded in the database. A 
description of the event, including the start date, resolution date, action taken, and the 
outcome should be provided, al ong with the Investigatorâ€™s as sessment of the relationship 
between the AE, the study treatment and the st udy procedure. This protocol will use common Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
terminology criteria for adverse events (CTCAE) version 4.0. For the AEs not characterized in 
the CTACE, the following definitions for rating severity of AEs will be used:  
Mild: Awareness of signs or symptoms, b ut easily tolerated; are of minor 
irritant type; causing no loss of time from normal activities; 
symptoms would not require medica tion or a medical evaluation; 
signs or symptoms are transient.
Moderate: Interferes with the patientâ€™s us ual activity and/or requires 
symptomatic treatment.
Severe: Symptom(s) causing severe discom fort and significant impact of 
the patientâ€™s usual activity and requires treatment.
A serious adverse event (SAE) is defi ned as an event which leads to:  
x Death due to any cause
x Life-threatening condition
x Results in persistent or sign ificant disability/incapacity
x Requires in-patient hospi[INVESTIGATOR_71014]
x Necessitates an interven tion to prevent a permanent impairment of a body 
function or permanent damage to a body structure
x Results in congenital abnormality
All SAEâ€™s will be reported.
For purposes of this study, the following events are not considered adverse events, 
because they are normally expected  to occur in conjunction post-surgery, or are associated with 
customary, standard care of patients undergoing these procedures:
xEarly post-operative pain (within 48hours po st-index procedure) at the incision site 
and/or related to position on procedure table
xPost-anesthesia emesis, nausea, or headache  (within [ADDRESS_77354]-index procedure)
xChest pain without associated ECG changes 
xElectrolyte imbalance withou t clinical sequalea follow ing endoscopic procedure, 
even if requiring correctionProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
xLow grade temperature increase ( d38.3qC/d101qF) 
xAny pre-planned surgical procedures
This listing of events is intended to prov ide guidance to the investigational sites for 
purposes of adverse event reporting.  The Investig ator at the investigational site should utilize 
his/her own clinical judgment in evaluating ad verse experiences and may decide that the above 
events should be report ed as adverse events.  
9.[ADDRESS_77355]  all serious adverse experiences that occur during the study 
period in the appropriate sour ce documents and/or AE log as  applicable. The study period 
for reporting serious adverse events (e.g., from  the time of signing consent to final study 
visit) should be indicated, wh o needs to be notified and the time frame for notification. If 
there are any specific reporting forms to be co mpleted, this should be indicated here. The 
Investigator will comply with regulations and institutional review board (IRB) policy 
regarding the reporting of adverse events.
If the PI [INVESTIGATOR_71015], the PI [INVESTIGATOR_71016]. Termination shal l occur not later than 5 working days after the 
PI [INVESTIGATOR_71017]  15 working days of PI [INVESTIGATOR_71018]. PI 
[INVESTIGATOR_71019] a terminat ed investigation withou t IRB and FDA approval.
10. Risk/Benefit Assessment
10.1 Potential Risks
xSkin or eye irritation from the aromatic  oils or other components of the patchProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
10.[ADDRESS_77356] Risks
xAppropriate patient selection
xContinual monitoring of the patient throughout the perioperative period
xAffixing of the aromatherapy patch to a towel placed next to the patientâ€™s head, rather 
than to the patientâ€™s gown or to their skin
xNo direct contact [CONTACT_71045] (saf ely contained in the pl astic envelope of the 
AromatabÂ® patch itself)
10.[ADDRESS_77357] of 1996 (HIPAA).
Patient data will be entered into a password protected electronic spreadsheet and online database (i.e., REDCap). Only the investigators, who have been invited to participate in the 
study and who are registered with the IRB, as we ll as have documented completion of all IRB 
and HIPAA regulations will have access to pati ent data, but not the medical record key. 
Electronic records will be stored for 5 years after study conclusion on the institutionâ€™s 
3URWRFRO
9HUVLRQ'DWH
3DJH RI
password protected computer, after which time th ey will be deleted. If there is a breach in 
confidentiality or violation of IRB and HIPAA regu lations, the IRB will be notified in a timely 
manner (within 7 days) and appropriate actions ta ken thereafter. All data used in the analysis 
and reporting of this investigation will be de -identified. Any photography shall be done in a 
discrete manner. Should images run the risk of enabling patient identification, identifying 
characteristics will be obscured electronically prior to publication.
In order to ensure compliance with the Heal th Insurance Portability and Accountability Act 
(HIPAA), all subjects enrolled in the study will be required to provide auth orization to disclose 
Protected Health Information (PHI). This auth orization will be included in the informed 
consent document as required by [CONTACT_1201]. In all study reports and in any resulting 
publications, subjects will not be  referred to by [CONTACT_56706]/or study identification 
number.
12. Sample Determinat ion and Data Analysis
12.1 Randomization
Once patients meet all inclusion criteria and after consenting, they will be randomized 
to receive either AromatabÂ® patch or placebo pa tch with a 1:1 allocation ratio. Concealment 
of treatment will occur until two hours prior to surgery. Patients and O.R. caregivers will 
not be blinded as to their study group (not feasible).
12.2 Sample Size Determination
This is a randomized controlled trial to  compare the time to readiness for discharge 
from PACU (minutes) after Port-a-Cath placem ent surgery between the patients who are 
randomized to receive intraoperative aromathe rapy (AromatabÂ® patch) versus placebo. We 
will enroll [ADDRESS_77358] 62 eligible and treated 
patients. Patients will be  randomized to receive either AromatabÂ® patch or placebo patch 
with a 1:1 allocation ratio. Th e primary objective of the study is to determine if patients
randomized to receive AromatabÂ® patch will ha ve a significantly shorter time to readiness Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
for discharge from PACU (minutes) after surgery when compared to patients who receive a 
placebo patch. The primary endpoint, time to  readiness for discharge from PACU after 
surgery, is defined as the time interval in min utes, from the end of surgery to the time when 
a patient is evaluated as ready to be disc harged from PACU. We observed from previous 
data on the patients treated with standard of  care (same as placebo) that the mean PACU 
duration was 66.[ADDRESS_77359] 80% power to detect a difference of [ADDRESS_77360] with a two-side d type I error rate of 0.05 (nQuery+nTerim 
4.0).
12.[ADDRESS_77361] deviations, medians, and ranges. Cate gorical demographic variables and clinical 
variables, such as gender, incidence, and inten sity of PONV, incidence of antiemetic use in 
PACU, will be summarized throug h frequencies and percentages. Fisherâ€™s exact test or Chi -
square test will be used to evaluate the as sociation between two categorical variables of 
interest. Wilcoxon-rank sum test or t-test wi ll be used to compare continuous outcomes 
such as time to readiness for discharge from PACU (minutes) after surgery between 
treatment groups. Linear/logistic  regression model may be fitted to assess the effect of 
important covariates on the primary/secondary endpoints.
12.4 Data Collection and Management
All study data will either be collected on a paper case report form (CRF) (which will be
entered into a computer database) or will be extracted directly from the EMR to the 
REDCap database. Each subject will be assigned a random number code and the key linking
the code and the subject identifier will be stored on an MD Anderson password protected 
computer. All changes to the CRF will foll ow Good Clinical Pract ice guidelines. TheProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
Research Manager is responsible for auditing the consistency of the data transcribed from
the paper CRF to the computer. A protocol viol ation log will be maintained, and all protocol
violations will be reported to the IRB.
Members of the research team  are responsible for transferring the information to the 
appropriate CRFs. The PI [INVESTIGATOR_71020], or as soon as poss ible after, the subjec t procedure or the av ailability of test 
results. The PI [INVESTIGATOR_71021](s) to verify that she has 
reviewed the recorded data. Upon PI [INVESTIGATOR_41473] , CRFs will be entered into the password 
protected REDCap database for analysis.
The PI [INVESTIGATOR_71022].Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
13. References
1. Johansson E, Engervall P, BjÃ¶rvell H, Hast R, BjÃ¶rkholm M. Patients' perceptions of 
having a central venous catheter or a to tally implantable subc utaneous port system-
results from a randomised study in acute leukaemia. Support Care Cancer. 2009 
Feb;17(2):137-43.
Giordano C, Pi[INVESTIGATOR_71023] A, Casciaro R, Simonini A (2018) Dexm edetomidine Infusion 
Perioperative to Control Agitation in Non-int ubated Young Patient wi th Cystic Fibrosis 
Undergoing Upper Arm Ultrasound Guided To tally Implantable Port-A-Cath Placement: 
A Case Report. Analg Resusc: Curr Res 7:1.
3. Chang DH, Hiss S, Herich L, Becker I, Ma mmadov K, Franke M, Mpotsaris A, Kleinert 
R, Persigehl T, Maintz D, Bangard C. Implan tation of venous access devices under local 
anesthesia: patients' satisfacti on with oral lorazepam. Patient Prefer Adherence. 2015 
Jul 7;9:943-9.
4. Schaal NK, BrÃ¼ckner J, Wolf OT, RuckhÃ¤berle E, Fehm T, Hepp P. The effects of a music 
intervention during port catheter placemen t on anxiety and stress. Sci Rep. 2021 Mar 
11;11(1):5807.
5. McDaniel C, Burkett AM, Corm ier M, Duvall J, Davis S, Gabriel L et al. PI[INVESTIGATOR_6875], The Music 
and Travel to the Port of Relaxation: The Effe cts of Music on Percei ved Pain and Anxiety 
in Patients Receiving PI[INVESTIGATOR_71024]-A -Caths. J Radiol Nu rs, 28(1), 32-34. 
6. Lv XN, Liu ZJ, Zhang HJ, Tzeng CM. Arom atherapy and the central nerve system 
(CNS): therapeutic mechanism and its ass ociated genes. Curr Drug Targets. 2013 
Jul;14(8):872-9.
7. Yuan R, Zhang D, Yang J, Wu Z, Luo C, Ha n L et al. Review of aromatherapy essential 
oils and their mechanism of action agains t migraines. J Ethnopharmacol. 2021 Jan 
30;265:[ADDRESS_77362] E. Is  lavender an anxiolytic drug? A systematic 
review of randomised clinical trials. Ph ytomedicine. 2012 Jun 15;19(8-9):825-35.
9. Wotman M, Levinger J, Leung L, Kallush A, Mauer E, Kacker A. The Efficacy of 
Lavender Aromatherapy in Reducing Preo perative Anxiety in Ambulatory Surgery Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
Patients Undergoing Procedures in Genera l Otolaryngology. Laryngoscope Investig 
Otolaryngol. 2017 Nov 8;2(6):437-441.
10. Jaruzel CB, Gregoski M, Mueller M, Fa ircloth A, Kelechi T. Aromatherapy for 
Preoperative Anxiety: A Pi[INVESTIGATOR_16116]. J Perianesth Nurs. 2019 Apr;34(2):259-264.
11.Beyliklio ÄŸluA, Arslan S. Effect of Lavender Oil on  the Anxiety of Patients Before Breast 
Surgery. J Perianesth Nurs. 2019 Jun;34(3):587-593.
12. Kim S, Kim HJ, Yeo JS, Hong SJ, Lee JM, Jeon  Y. The effect of la vender oil on stress, 
bispectral index values, and needle insertion pain in volunteers. J Altern Complement 
Med. 2011 Sep;17(9):823-6.
13. Grigoleit HG, Grigoleit P. Pharmacolo gy and preclinical ph armacokinetics of 
peppermint oil. Phytomedicine. 2005 Aug;12(8):612-6.
14. Hines S, Steels E, Chang A, Gibbons K. Arom atherapy for treatment of postoperative 
nausea and vomiting. Cochrane Database of Systematic Revi ews 2018, Issue 3. Art. No.: 
CD007598. DOI: 10.1002/14651858.CD00759 8.pub3. Accessed [ADDRESS_77363] of Inhalation 
Aromatherapy with 10% and 30% Peppermint Es sential Oils on the Severity of Nausea 
in Abdominal Surgery Patients. Evid Base d Complement Alternat Med. 2020 Apr 
20;2020:5897465. 
16. Maghami M, Afazel MR, Azizi-Fini I, Ma ghami M. The effect of aromatherapy with 
peppermint essential oil on nausea and vomi ting after cardiac surgery: A randomized 
clinical trial. Complement Ther Clin Pract. 2020 Aug;40:101199.
17. Grant MC, Kim J, Page AJ, Hobson D, Wi ck E, Wu CL. The Effect of Intravenous 
Midazolam on Postoperative Nausea and Vo miting: A Meta-Analysis. Anesth Analg. 
2016 Mar;122(3):656-663.
18.Aldrete JA, Kroulik D. A postanesthetic re covery score. Anesth Analg. 1970 Nov-
Dec;49(6):924-34.
19. Aldrete JA. Modifications to the postanesth esia score for use in ambulatory surgery. J 
Perianesth Nurs. 1998 Jun;13(3):148-55.
20.Apfel CC, Heidrich FM, Jukar-Rao S, Ja lota L, Hornuss C, Whelan RP, Zhang K, 
Cakmakkaya OS. Evidence-based  analysis of risk factors for postoperative nausea and 
vomiting. Br J Anaesth. 2012 Nov;109(5):742-53.
3URWRFRO
9HUVLRQ'DWH
3DJH RI
14. Appendixes 
Calendar of Events
Data collection forms
Appendix 1: Calendar of Events
Visit Window Screening Intra-op Post-op
Subject Recruitment x
Enrollment/Pt 
educationx
Medical Record 
Documentationx x x
CRF completion x xProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
Appendix 2: Data  Collection Forms
ELIGIBILITY
Study #: _____________
MRN:      _____________
Inclusion criteria
xAdult patients ( â‰¥18 years old)                  Yes / No
xUndergoing Port-a-Cath placement surgery under      Yes / No 
Monitored Anesthesia Care
xSigned informed consent form      Yes / No
Exclusion criteria
xPatients undergoing other surgical procedures                                           Yes / No
during Port-a-Cath placem ent (including explantation
of a Port-a-Cath or other prev ious vascular access device)
xPatients requiring general anesthesia or th ose not eligible for MAC       Yes / No
xPatients allergic or sensitive to plants, essentia l oils, or                   Yes / No
any of the medications used in this study
            
xPatients with history of G6PD defici ency              Yes / No
xPatients with history of atrial fibrillation        Yes / No
xPatients unable to complete study questionnaires        Yes / No
xPatients who are completely anosmic or who have history        Yes / No
of intolerance to aromatherapy
xPatients who have been taking any opi[INVESTIGATOR_70996] 90 days or more        Yes / No
xPatients who have been taking  any benzodiazepi[INVESTIGATOR_71025] 
30 days or more                                                                      Yes / NoProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
DEMOGRAPHIC AND PREOPERATIVE DATA
Study #: _________
MRN:  _____________
Age: _______________Sex:  Female/Male
Ethnicity: (Circle all that applies)
Caucasian      Black      Hi spanic     Asian.    Other
Height (cm):   ______________  Weight (kg): ____________ 
Body Mass Index (BMI) __________________________________
ASA (Circle one):  1   2   3   4
CURRENT CANCER (Circle all that applies)
Breast   Malignant bone tumor   Lung   Urologic al   Gastrointestinal    Head and Neck    
Genitourinary   Skin    Centra l nervous system    Lymphoma     Leukemia      Myeloma
Other Unknown
MEDICAL HISTORY 
Oncology History (other than primary) Yes/No If yes, please circle all that applies:
Breast   Malignant bone tumor   Lung   Urologic al   Gastrointestinal    Head and Neck    
Genitourinary   Skin    Centra l nervous system    Lymphoma     Leukemia      Myeloma
Other Unknown
Charlson Comorbidities 
Myocardial infarction (+1)
Congestive heart failure (+1)
Peripheral vascular disease (+1)
Cerebrovascular disease (except hemiplegia) (+1)Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
Dementia (+1)
Chronic pulmonary disease (+1)
Connective tissue disease (+1)
Ulcer disease (+1)
Mild liver disease (+1)
Diabetes (without complications) (+1)
Diabetes with end- organ damage (+2)
Hemiplegia (+2)
Moderate or severe renal disease (+2)
Solid tumor (non-metastatic) (+2)
Leukemia (+2)
Lymphoma, multiple myeloma (+2)
Moderate or severe liver disease (+3)
Metastatic solid tumor (+6)
AIDS (+6)
(Check all that apply)
Comorbidity Score
__________________________________
Please select a patient age range 50 - 59 (+1)
60 - 69 (+2)
70 - 79 (+3)
80 - 89 (+4)
90 - 99 (+5)
Age Score
__________________________________
Total Charlson Comorbidities Score
__________________________________
History of Smoking (Pleas e check appropriate box.)
â–¡ Current smoker  
â–¡ Quit smoking: within  30 days of surgery 
â–¡ Quit smoking: 1 month to  1 year before surgery 
â–¡ Quit smoking: more than  1 year before surgery 
3URWRFRO
9HUVLRQ'DWH
3DJH RI
â–¡ Never smoked
PREOPERATIVE ANALGESIA
Pain Intensity (Circle one) : 0  1  2  3  4  5  6  7  8  9  10  N/A
(Verbal numeric rating scale: 0: no pain â€“10: worst pain possible)
Preoperative Opi[INVESTIGATOR_71026]____No____ Prescribed since when?________
Fentanyl amount/day  (mcg)  ________   (Please enter 0 if not taking)
Hydrocodone amount/day (mg) ______ __ (Please enter 0 if not taking)
Hydromorphone amount/day (mg) ____ ___(Please enter 0 if not taking)
Methadone amount/day (mg) ________   (Please enter 0 if not taking)
Morphine amount/day (mg) ________   (Please enter 0 if not taking)
Oxycodone amount/day (mg) ________   (Please enter 0 if not taking)
Oxymorphone amount/day (mg) ________    (Please enter 0 if not taking)
Tramadol amount/day (mg) ________   (Please enter 0 if not taking)
Codeine amount/day (mg) ________   (Please enter 0 if not taking)
Other Opi[INVESTIGATOR_2438] (Write name [CONTACT_13691]) ____________
Preoperative Morphine Equivalent Daily Dose:________   
Preoperative NSAIDs   Yes____ N0______(Ch eck all that apply)
Ibuprofen amount/day (mg) ________   (Please enter 0 if not taking)
Naproxen amount/day (mg) ________   (Please enter 0 if not taking)
Meloxicam amount/day (mg) ________   (Please enter 0 if not taking)
Ketorolac amount/day (mg) ________   (Please enter 0 if not taking)
Diclofenac amount/day (mg) ________   (Please enter 0 if not taking)
Celecoxib amount/day (mg) ________   (Please enter 0 if not taking)
Other preoperative NSAID (Write name [CONTACT_13691])
__________________________________
Preoperative Gabapentinoids Yes____ N0______(Check all that apply)
Gabapentin amount/day (mg) ________    (Please enter 0 if not taking)
Pregabalin amount/day (mg) ________    (Please enter 0 if not taking)Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
Preoperative Acetaminophen Yes____ N0______
If yes, amount/day (mg) ______
Preoperative benzodiazepi[INVESTIGATOR_71027]____No____ Prescribed since when?______
Diazepam amount/day (mg) ________   (Please enter 0 if not taking)
Alprazolam amount/day (mg) ________    (Please enter 0 if not taking)
Triazolam amount/day (mg) ________   (Please enter 0 if not taking)
Lorazepam amount/day (mg) ________   (Please enter 0 if not taking)
Clonazepam amount/day (mg) ________   (Please enter 0 if not taking)
Midazolam amount/day (mg)__________ _(Please enter 0 if not taking)
Preoperative antiemetics
Ondansetron amount/day (mg)  ________    (Please enter 0 if not taking)
Granisetron amount/day (mg) ________ (Please enter 0 if not taking)
Aprepi[INVESTIGATOR_71028]/day (mg) ______ _(Please enter 0 if not taking)
Promethazine amount/day (mg) ________   (Please enter 0 if not taking)
Droperidol amount/day (mg) ________    (Please enter 0 if not taking)
Metoclopramide amount/day (mg) ________    (Please enter 0 if not taking)
Scopolamine patch amount/day  (mg) ________   (Please enter 0 if not taking)
Apfel-Score for PONV
Gender                 Male 0 / Female: +1
Smoking status     Smoker 0 / Non-smoker +1
History of motion sickne ss or PONV No 0 / Yes +1
Use of postoperative Opi[INVESTIGATOR_2480] s No: 0    /   Yes  +1
Total points:_______    
3URWRFRO
9HUVLRQ'DWH
3DJH RI
HOSPI[INVESTIGATOR_71029]#: _________________
MRN:    _________________
Tick the box beside the repl y that is closest to how yo u have been feeling in the 
past week. Donâ€™t take too long over yo ur replies: your immediate is best.
1. I feel tense or 'wound up' 
oNot at all
oFrom time to ti me, occasionally
oA lot of the time
oMost of the time
2. I get a sort of frightened feeling as if something awful is about to happen.
oNot at all
oA little but it doesn't worry me
oYes, but not too badly
oVery definitely and quite badly
3. Worrying thoughts go through my mind 
oOnly occasionally
oFrom time to time , but not too often
oA lot of the time
oA great deal of the time
4. I can sit at ease and feel relaxed 
oDefinitely
oUsually
oNot Often
oNot at all
5. I get a sort of frightened feeling like 'butterflies' in the stomach.
oNot at all
oOccasionally
oQuite Often
oVery Often
6. I feel restless as I have to be on the move.
oNot at all
oNot very much
oQuite a lot
oVery much indeed
7. I get sudden feelings of panic.
oNot at all
oNot very often
oQuite oftenProprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
oVery often indeed
8. I still enjoy the things I used to enjoy.
oDefinitely as much
oNot quite as much
oOnly a little
oHardly at all
9. I can laugh and see the funny side of  things as much as I always could.
oNot quite so much now
oDefinitely not so much now
oNot at all
10. I feel cheerful.
oMost of the time
oSometimes
oNot often
oNot at all
11. I feel as if I am slowed down.
oNot at all
oSometimes
oVery often
oNearly all the time
12. I have lost interest in my appearance.
oI take just as much care as ever
oI may not take quite as much care
oI don't take as much care as I should
oDefinitely
13. I look forward with enjoyment to things.
oAs much as I ever did
oRather less than I used to
oDefinitely less than I used to
oHardly at all
14. I can enjoy a good book or radio or TV program.
oOften
oSometimes
oNot often
oVery seldom
3URWRFRO
9HUVLRQ'DWH
3DJH RI
SEDATION AND INTRAOPERATIVE DATA
Study #: _____________
MRN:     _____________
Randomization:   Active treatment / placebo
Date of Surgery. ___/___/___
Procedure Start Time: ______:_____. Procedure End Time: ______:______. 
Duration of Surgery (min): _______. 
Sedation
Sedation Start Time (placeme nt of patch): ______:_____. 
Sedation End Time (removal of patch): ______:______. 
Duration of sedation (min): _______. 
Midazolam given:   Yes / No      If yes: total dose (mg): ______
Analgesia
Intraoperative Acetaminophen:  Yes / No      If yes: to tal dose (mg): ____
Intraoperative Opi[INVESTIGATOR_71030]: Yes / No      If  yes: total dose (mg): ____
Hydromorphone: Yes / No      If yes: total dose (mg): ____
Other (Name [CONTACT_13691]): ______________ 
Rescue antiemetics
Dexamethasone: Yes / No  If  yes: total dose (mg): ____
Ondansetron: Yes / No       If yes: to tal dose (mg): ____.                                      
Granisetron: Yes / No         If yes: total dose (mg): ____
Promethazine: Yes / No      If yes: total dose (mg): ____
Propofol: Yes / No                If yes: to tal dose (mg): ____
Any AE/SAE: __________ Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
POSTOPERATIV DATA â€“PACU
Study #: ______________
MRN:     ______________
Time of admission to PACU: ______/________
Time of discharge from PACU: ______/________
Verbal numerical Pain Score, Aldrete Pars ap Recovery Score, nausea intensity and 
the number of vomiting epi[INVESTIGATOR_71031] 15 minutes from Anesthesia 
end until a Parsap Score â‰¥ 18 is reached. Patient Satisfac tion is assessed as soon as 
a Parsap Score â‰¥18 has been reached. 
Aldrete Parsap Recovery Score
Indices Task Score
ActivityAble to move four extremities voluntarily or on command
Able to move two extremities voluntarily or on command
Unable to move extremities voluntarily or on command2
1
0
Respi[INVESTIGATOR_71032], limited breathing or tachypnea
Apneic or on mechanical ventilator2
1
0
CirculationBP Â± 20% of pre-anesthetic level
BP Â± 20 - 49% of pre-anesthetic level
BP Â± 50% of pre-anesthetic level2
1
0
ConsciousnessFully awake
Arousable on calling
Not responding2
1
0
O2 SaturationAble to maintain O 2saturation > 92% on room air
Needs O 2inhalation to maintain O 2saturation > 90%
O2saturation <90% even with O 2supplement2
[ADDRESS_77364]
Dizziness when supi[INVESTIGATOR_050]2
1
0
Fasting- FeedingAble to drink fluids
Nauseated
Nausea and vomiting2
1
0
Urine OutputHas voided
Unable to void but comfortable
Unable to void and uncomfortable2
1
0Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
T1: ______/________ Score: ________
T2: ______/________ Score: ________ if patient is still admitted to PACU
T3: ______/________ Score: ________ if patient is still admitted to PACU
T4: ______/________ Score: ________ if patient is still admitted to PACU
T5: ______/________ Score: ________ if patient is still admitted to PACUT6: ______/________ Score: ________ if patient is still admitted to PACU
T7: ______/________ Score: ________ if patient is still admitted to PACU
T8: ______/________ Score: ________ if patient is still admitted to PACU
T9: ______/________ Score: ________ if patient is still admitted to PACU
T10: ______/________ Score: _______  if patient is still admitted to PACU
Pain intensity (VNRS, 0: no pain â€“10: worst pain possible)
T1: ______/________ Score: ________
T2: ______/________ Score: ________ if patient is still admitted to PACU
T3: ______/________ Score: ________ if patient is still admitted to PACU
T4: ______/________ Score: ________ if patient is still admitted to PACU
T5: ______/________ Score: ________ if patient is still admitted to PACU
T6: ______/________ Score: ________ if patient is still admitted to PACU
T7: ______/________ Score: ________ if patient is still admitted to PACU
T8: ______/________ Score: ________ if patient is still admitted to PACU
T9: ______/________ Score: ________ if patient is still admitted to PACU
T10: ______/________ Score: _______  if patient is still admitted to PACU
Postoperative Analgesics
Acetaminophen: Yes / No If ye s dose (mg)____ route: po/iv
NSAIDs 
Celecoxib: Yes / No If yes dose (mg)__ __ route: po/iv___time first dose:___:___
Ketorolac: Yes / No If yes dose (mg)____ route: po/iv
Ibuprofen: Yes / No If yes dose (mg)____ route: po/iv
Naproxen: Yes / No If yes dose (mg)____ route: po/ivOther: Yes / No If yes d ose (mg)____ route: po/iv
Postoperative Opi[INVESTIGATOR_71033]: Yes / No If yes dose (mg)____ route: po/iv___time first dose:___:___
Hydromorphone: Yes / No If yes dose (mg) ____ route: po/iv___ti me first dose:___:___
Morphine: Yes / No If yes dose (mg)____  route: po/iv___time first dose:___:___
Hydrocodone: Yes / No If yes dose (mg)____  route: po/iv___time first dose:___:___
Tramadol: Yes / No If yes dose (mg)____  route: po/iv___time first dose:___:___Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
Oxycodone: Yes / No If yes dose (mg)__ __ route: po/iv___time first dose:___:___
Codeine: Yes / No If yes dose (mg)____ route: po/iv___time first dose:___:___
Other: Yes / No If yes dose (mg)____  route: po/iv___time first dose:___:___
Nausea intensity (VNRS, 0: no nausea â€“10: worst nausea possible)
T1: ______/________ Score: ________T2: ______/________ Score: ________ if patient is still admitted to PACU
T3: ______/________ Score: ________ if patient is still admitted to PACU
T4: ______/________ Score: ________ if  patient is still admitted to PACU
T5: ______/________ Score: ________ if patient is still admitted to PACU
T6: ______/________ Score: ________ if patient is still admitted to PACU
T7: ______/________ Score: ________ if patient is still admitted to PACU
T8: ______/________ Score: ________ if patient is still admitted to PACU
T9: ______/________ Score: ________ if patient is still admitted to PACU
T10: ______/________ Score: _______  if patient is still admitted to PACU
Vomiting: Yes / No Time of first occurrence of vomiting. ____:______
Vomiting epi[INVESTIGATOR_71034]1: ______/________ Number: ________
T2: ______/________ Number: ________ if patient is still admitted to PACU
T3: ______/________ Number: ________ if patient is still admitted to PACU
T4: ______/________ Number: ________ if  patient is still admitted to PACU
T5: ______/________ Number: ________ if patient is still admitted to PACU
T6: ______/________ Number: ________ if  patient is still admitted to PACU
T7: ______/________ Number: ________ if  patient is still admitted to PACU
T8: ______/________ Number: ________ if  patient is still admitted to PACU
T9: ______/________ Number: ________ if  patient is still admitted to PACU
T10: ______/________Number: _______  if patient is still admitted to PACU
Ondansetron: Yes / No If yes: dose (mg) ____ route: po/iv___time first dose:___:___
Granisetron: Yes / No If yes: dose (mg)__ __ route: po/iv___time first dose:___:___
Promethazine: Yes / No If yes: dose (mg)__ __ route: po/iv___time first dose:___:___
Other:______ Yes / No If yes: dose (mg) ____ route: po/iv___time firstdose:___:___
Likert Scale for patient satisfaction (circle one)
Satisfaction level Score
Very much satisfied 5
Somewhat satisfied 4
Undecided 3
Not really satisfied 2
Not at all satisfied 1Proprietary of MD Anderson Cancer Center
3URWRFRO
9HUVLRQ'DWH
3DJH RI
There are no screening tests or blood draws require to enter the study. 
We expect 70 patients here at MD Anderson Cancer Center to agree and participate in the 
study.
Prior to surgery, subjects will be randomized 1:1 to either a lavender/peppermint patch of 
Elequis AromatabsÂ®, or a matching placebo patch.